Amir Mortazavi

7PUBLICATIONS
78CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 02, 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Andrea B Apolo, Daniel M Girardi, Scot A Niglio

|Jan 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.

Samuel A Funt, Michael Lattanzi, Karissa Whiting

|Jan 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.

Daniel M Girardi, Scot A Niglio, Amir Mortazavi

|May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).

Jonathan E Rosenberg, Karla A Ballman, Susan Halabi

|Jan 25, 2021
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.

Katharine A Collier, Hugo Valencia, Herbert Newton

|Dec 02, 2020
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.

Heather J Chalfin, Tiziano Pramparo, Amir Mortazavi

Pageof 2

Frequent Collaborators

4 joint publications

Donald P Bottaro

3 joint publications

Andrea B Apolo

3 joint publications

Rosa Nadal

3 joint publications

Daniel M Girardi